3 ms·
I've no doubt that immediately prior to the expiry, a newer formulation with some other advantage will be released, thereby renewing the need to buy drugs under
by MPSimmons 2y ago
I've no doubt that immediately prior to the expiry, a newer formulation with some other advantage will be released, thereby renewing the need to buy drugs under patent.
- ChadNauseam 2y agoI definitely hope that newer formulations with various advantages are released. In fact it seems like they are already on the way with Tirzepatide (a GLP-1 and GIP analogue). More distant are GLP-1/GIP/Glucagon agonists, which are likely to be more effective still. However I doubt that Novo's competitors which are researching this drug will kindly wait for Novo's patent to run out before releasing them.
- 0cf8612b2e1e 2y agoGeneric manufacturers have nothing to lose by selling the v1 Ozempic. Sure, maybe it is less good along some dimension, but if it is effective and X% of the v2 formulation price, going to come down to economics.